Citations

Showing 10 of 107940 citations.

Refining Rehabilitation With Proprioception Training
Laskowski, Edward R. , Newcomer‐Aney, Karen, Smith, Jay

Mayo Clinic

The Physician and Sportsmedicine | May 13, 2010 | Volume: 25 | Issue: 10 | Pages: 89-102

10.3810/psm.1997.10.1476 | PMID 20086861 Get It

Weight Training Injuries
Reeves, Ronald K. , Laskowski, Edward R. , Smith, Jay

Mayo Clinic

The Physician and Sportsmedicine | May 13, 2010 | Volume: 26 | Issue: 2 | Pages: 67-96

10.3810/psm.1998.02.939 | PMID 20086781 Get It

Proteome Analysis of Human Aqueous Humor
Chowdhury, Uttio Roy, Charlesworth, Mary Christine, Fautsch, Michael P. , Madden, Benjamin J.

Mayo Clinic

Investigative Opthalmology & Visual Science | May 13, 2010 | Volume: 51 | Issue: 10 | Pages: 4921

10.1167/iovs.10-5531 | PMID 20463327 Get It

A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Two Schedules of Vorinostat in Combination with 5-Fluorouracil and Leucovorin in Patients with Refractory Solid Tumors
Fakih, Marwan , Fetterly, Gerald J., Egorin, Merrill J., Muindi, Josephia R., Espinoza‐Delgado, Igor, Litwin, Alan, Holleran, Julianne L. , Wang, Kangsheng , Diasio, Robert B. , Zwiebel, James A. , Fakih, Marwan

Mayo Clinic

Clinical Cancer Research | May 13, 2010 | Volume: 16 | Issue: 14 | Pages: 3786-3794

10.1158/1078-0432.ccr-10-0547 | PMID 20463088 Get It

AbstractPurpose: We conducted a phase I clinical trial to determine the maximum tolerated dose (MTD) of daily or twice daily vorinostat × 3 days when combined with fixed doses of 5-fluorouracil (FU) and leucovorin every 2 weeks.Experimental Design: Vorinostat doses were escalated in a standard 3 × 3 phase I design. FU/leucovorin was started on day 2 of vorinostat and consisted of leucovorin 400 mg/m2 i.v. over 2 hours followed by FU 400 mg/m2 i.v. bolus and 2,400 mg/m2 over 46 hours (sLV5FU2).Results: Forty-three patients were enrolled. Grade 3 fatigue, and hand and foot syndrome were the dose-limiting toxicities (DLT) at the 2,000 mg vorinostat once-daily dose level. Grade 3 fatigue and mucositis were DLTs at the 800 mg vorinostat twice-daily dose level. None of six patients at the 1,700 mg once daily or six patients at the 600 mg twice daily dose levels had a DLT; those dose levels represent the MTD. Twenty-one of 38 patients with FU-refractory colorectal cancer had stable disease, and one had a partial response. Vorinostat maximum serum concentrations at the MTD exceeded concentrations associated with thymidylate synthase downregulation in vitro. No pharmacokinetic interactions were noted between vorinostat and FU.Conclusions: The MTD of vorinostat in combination with sLV5FU2 is 1,700 mg orally once daily × 3 or 600 mg orally twice daily × 3 days every 2 weeks. Clinical activity in refractory colorectal cancer supports further clinical development of this combination. Clin Cancer Res; 16(14); 3786–94. ©2010 AACR.
Commentary: Chronic Lymphocytic Leukemia—The Price of Progress
Gunderson, Heidi D, Call, Timothy G. , Shanafelt, Tait D.

Mayo Clinic

The Oncologist | May 13, 2010 | Volume: 15 | Issue: 6 | Pages: 601-602

10.1634/theoncologist.2010-0090 | PMID 20463087 Get It

The study looks at the high cost of new treatments for chronic lymphocytic leukemia and calls for the consideration of a standardized and transparent method to determine the price of new drugs based on comparative effectiveness.
Productive Replication of vif -Chimeric HIV-1 in Feline Cells
Stern, Melissa A., Hu, Chunling , Saenz, Dyana T. , Fadel, Hind J., Sims, Olivia, Peretz, Mary, Poeschla, Eric M. , Sims, Olivia L., Hu, Chunling

Mayo Clinic

Journal of Virology | May 13, 2010 | Volume: 84 | Issue: 14 | Pages: 7378-7395

10.1128/jvi.00584-10 | PMID 20463079 Get It

ABSTRACT Nonprimate animal models of HIV-1 infection are prevented by missing cellular cofactors and by antiviral actions of species-specific host defense factors. These blocks are profound in rodents but may be less abundant in certain Carnivora. Here, we enabled productive, spreading replication and passage of HIV-1 in feline cells. Feline fibroblasts, T-cell lines, and primary peripheral blood mononuclear cells supported early and late HIV-1 life cycle phases in a manner equivalent to that of human cells, except that produced virions had low infectivity. Stable expression of feline immunodeficiency virus (FIV) Vif-green fluorescent protein (GFP) in HIV-1 entry receptor-complemented feline (CrFK) cells enabled robust spreading HIV-1 replication. FIV Vif colocalized with feline APOBEC3 (fA3) proteins, targeted them for degradation, and prevented G→A hypermutation of the HIV-1 cDNA by fA3CH and fA3H. HIV-1 Vif was inactive against fA3s as expected and even paradoxically augmented restriction in some assays. In an interesting contrast, simian immunodeficiency virus SIVmac Vif had substantial anti-fA3 activities, which were complete against fA3CH and partial against fA3H. Moreover, both primate lentiviral Vifs colocalized with fA3s and could be pulled down from cell lysates by fA3CH. HIV-1 molecular clones that encode FIV Vif or SIVmac Vif (HIV-1 VF and HIV-1 VS ) were then constructed. These viruses replicated productively in HIV-1 receptor-expressing CrFK cells and could be passaged serially to uninfected cells. Thus, with the exception of entry receptors, the cat genome can supply the dependency factors needed by HIV-1, and a main restriction can be countered by vif chimerism. The results raise the possibility that the domestic cat could yield an animal model of HIV-1 infection.
Early atherosclerosis aggravates the effect of renal artery stenosis on the swine kidney
Urbieta-Caceres, Victor H., Lavi, Ronit, Zhu, Xiang-Yang, Crane, John A., Textor, Stephen C., Lerman, Lilach O. , Lerman, Amir

Mayo Clinic

American Journal of Physiology-Renal Physiology | May 13, 2010 | Volume: 299 | Issue: 1 | Pages: F135-F140

10.1152/ajprenal.00159.2010 | PMID 20462971 Get It

Atherosclerotic renal artery stenosis (ARAS) is increasingly identified in patients with end-stage renal disease. Renal function in ARAS patients deteriorates more frequently than in nonatherosclerotic renal artery stenosis (RAS). This study was designed to test the hypothesis that atherosclerosis modifies the relationship between single-kidney hemodynamics and function and the severity of stenosis. The degree of unilateral RAS in domestic pigs (4 normal, 26 RAS, and 22 ARAS) was correlated with renal function and hemodynamics evaluated by 64-slice multidetector computerized tomography before and after endothelium-dependent challenge with ACh. The degree of stenosis and increase in mean arterial pressure were similar in RAS and ARAS. Stenotic single-kidney volume, blood flow, glomerular filtration rate, and cortical perfusion were lower than normal in both RAS and ARAS, but only in RAS correlated inversely with increasing degree of stenosis ( r = −0.62, r = −0.49, r = −0.51, and r = −0.46, respectively, P < 0.05 for all). Basal tubular fluid concentration capacity and stenotic cortical perfusion response to ACh were both blunted only in ARAS. This study shows that atherosclerosis modulates the impact of a stenosis in the renal artery on stenotic kidney hemodynamics, function, and tubular dynamics. These observations underscore the direct intrarenal effect of atherogenic factors on the kidneys.
The Changing Spectrum of Fungal Infections In Pulmonary and Critical Care Practice: Clinical Approach To Diagnosis
Limper, Andrew H.

Mayo Clinic

Proceedings of the American Thoracic Society | May 12, 2010 | Volume: 7 | Issue: 3 | Pages: 163-168

10.1513/pats.200906-049al | PMID 20463243 Get It

Abstract Fungal lung infections are being diagnosed with increasing frequency. This is related to the increased numbers of immune-compromised and other susceptible patient groups. This article will focus on the evolving epidemiology of fungal lung infections and clinical manifestations that should prompt the clinician to consider the possibility of fungal lung infection. In addition, current approaches for the diagnosis of these infection are also reviewed. Heightened awareness of fungal lung infection, and appropriate use of the available diagnostic modalities, will permit appropriate treatment of these important clinical infections in immune-compromised individuals.
T Cell Activation at the Immunological Synapse: Vesicles Emerge for LATer Signaling
Billadeau, Daniel D.

Mayo Clinic

Science Signaling | May 11, 2010 | Volume: 3 | Issue: 121 | Pages: No page available

10.1126/scisignal.3121pe16 | PMID 20460646 Get It

Subsynaptic vesicles that contain the adaptor protein linker of activated T cells regulate T cell signaling.
Proton pump inhibitor treatment for acute peptic ulcer bleeding
Sharma, Virender Kumar , Leontiadis, Grigorios I. , Howden, Colin W.

Mayo Clinic

Cochrane Database of Systematic Reviews | May 11, 2010 | Volume: 2010 | Issue: 5 | Pages: No page available

10.1002/14651858.cd002094.pub4 | PMID 20464720 Get It